Vnitřní lékařství 1/2020

HLAVNÍ TÉMA Aterogenní dyslipidemie typické pro metabolický syndrom 20 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(1): 15–20 /  www.casopisvnitrnilekarstvi.cz 12. Kelley GA, Kelley KS. Effects of aerobic exercise on lipids and lipoproteins in adul‑ ts with type 2 diabetes: a meta‑analysis of randomizedcontrolled trials. Public Health 2007; 121: 643–655. 13. Gower BA, Goss AM. A lower‑carbohydrate, higher‑fat diet reduces abdominal and in‑ termuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes. J Nutr 2015; 145: 177S–83S. 14. Tay J, Luscombe‑Marsh ND, Thompson CH et al. A very lowcarbohydrate, low­ ‑saturated fat diet for type 2 diabetes management: a randomized trial. Diabetes Care 2014; 37: 2909–2918. 15. Wycherley TP, Thompson CH, Buckley JD et al. Long‑term effects of weight loss with a very‑low carbohydrate, low saturated fat diet on flow mediated dilatation in patients with type 2 diabetes: a randomised controlled trial. Atherosclerosis 2016; 252: 28–31. 16. Gaede P, Lund‑Andersen H, Parving HH, Pedersen O. Effect of a multifactorial interven‑ tion on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–591. 17. The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle inter‑ vention in type 2 diabetes. N Engl J Med 2013; 369: 145–154. 18. Mach F, Baigent C, Catapano AL et al. [ESC Scientific Document Group]. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardio‑ vascular risk. Eur Heart J 2019; pii: ehz455. Dostupné z DOI: <http://dx.doi.org/10.1093/ eurheartj/ehz455. 19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cho‑ lesterol lowering with simvastatin in 20536 high‑risk individuals: a randomised placebo­ ‑controlled trial. Lancet 2002;360: 7–22. 20. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disea‑ se in men and women with diabetes compared with non‑diabetic people: a population­ ‑based retrospective cohort study. Lancet 2006; 368: 29–36. 21. Anderson TJ, Gregoire J, Pearson GJ et al. 2016 Canadian Cardiovascular Society gui‑ delines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2016; 32: 1263–1282. 22. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–2397. 23. The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–364. 24. Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta‑analysis. Lancet 2010; 375: 1875–1884. 25. ElamMB, Ginsberg HN, Lovato LC et al. Association of fenofibrate therapy with long‑term cardiovascularrisk instatin‑treatedpatientswithtype2diabetes.JAMACardiol2017;2:370–380. 26. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardi‑ ovascular risk. Am J Cardiol 2008; 101: S58–62. 27. The HPS2-THRIVE Collaborative Group. Effects of extended‑release niacin with laropi‑ prant in high‑risk patients. N Engl J Med 2014; 371: 203–212. 28. The AIM‑HIGH Investigators. Niacin in patients with low HDL cholesterol levels recei‑ ving intensive statin therapy. N Engl J Med 2011; 365: 2255–2267. 29. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in pati‑ ents with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722. 30. Leiter LA, Cariou B, Muller‑Wieland D et al. Efficacy and safety of alirocumab in insulin­ ‑treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODY‑ SSEY DM‑INSULIN randomized trial. Diabetes Obes Metab. 2017; 19: 1781–1792 31. Ray KK, Leiter LA, Muller‑Wieland D et al. Alirocumab vs usual lipid‑lowering care as add‑on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM DYSLIPIDEMIA randomized trial. Diabetes Obes Metab. 2018; 20: 1479–1489. 32. Cicali R, Di Pino A, Ferrari V, Urbano F, Piro S, Rabuazzo AM, Purrello F. New treatment options for lipid‑lowering therapy in subjects with type 2 diabetes. Acta Diabetologica (2018); 55: 209–218. 33. Gouni‑Berthold I, Alexander V, Digenio A et al. Apolipoprotein C‑III inhibition with vo‑ lanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double‑blind, placebo‑controlled trial. J Clin Lipidol 2017; 11: 794–795.